Trials / Completed
CompletedNCT03386825
Metastatic Colorectal Cancer Patients With Long-term Response to Regorafenib
COLONG: Metastatic Colorectal Cancer Patients With Long-term Response to Regorafenib
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 76 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this local NIS(Non-Interventional Study) is to determine the proportion of Belgian patients with a duration of treatment(DoT) to Stivarga of 4 months or more in relation to the total population of Belgian metastatic colorectal cancer(mCRC) patients who were treated with Stivarga between the 1st of July 2015 and 31 July 2017. In addition, this study aims to describe the clinical characteristics of Belgian patients with a short- or long-term DoT to Stivarga.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Regorafenib (Stivarga, BAY73-4506) | Antineoplastic agents, protein kinase inhibitor (L01XE21) |
Timeline
- Start date
- 2018-01-31
- Primary completion
- 2018-05-01
- Completion
- 2018-05-01
- First posted
- 2017-12-29
- Last updated
- 2018-05-15
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT03386825. Inclusion in this directory is not an endorsement.